The Council of the Queensland Institute of Medical Research

Mcgill University

Id Biomedical Corporation of Quebec

Michael Good

George H Lowell

David S Burt

George L White

Michael R Batzloff

Mary M Stevenson

Tomas B Leanderson

The present invention relates to an immunogenic agent comprising a low dose of an antigenic component from one or more pathogens and an agent capable of increasing an amount of IL-12 in animal, and use thereof for reducing infection or improving recovery from an infection from the pathogen. The immunogenic agent preferably comprises CpG nucleic acid, IL-12 protein and/or IL-12 nucleic acid. The pathogen is preferably an intracellular pathogen comprising one or more species and strains, such asspp. The invention also relates to a pharmaceutical composition comprising the immunogenic agent. The pharmaceutical composition is preferably an immunotherapeutic composition. The immunotherapeutic composition, is preferably a vaccine capable of providing protection against or treatingspp infection, the causative agent of malaria in humans.

Immunogenic agent and pharmaceutical composition for use against homologous and heterologous pathogens including plasmodium SPP

Effective stimulation of immune responses is achieved through the use of a group A streptococcal antigen combined with proteosome adjuvant. The compositions are provided in particular for intranasal administration. The vaccine compositions are provided for use in inducing an immune response in an individual for the treatment or prophylaxis of group A streptococcal infection in an individual, preferably via prevention or reduction of colonisation of the throat following intranasal administration.

Vaccine

Growing community of inventors

The Gap, Australia

Michael Good